Evoke Pharma Basic EPS 2012-2024 | EVOK
Evoke Pharma basic eps from 2012 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| Evoke Pharma Annual Basic EPS |
| 2023 |
$-27.97 |
| 2022 |
$-31.45 |
| 2021 |
$-38.18 |
| 2020 |
$-74.94 |
| 2019 |
$-46.12 |
| 2018 |
$-66.29 |
| 2017 |
$-118.18 |
| 2016 |
$-165.73 |
| 2015 |
$-269.50 |
| 2014 |
$-317.05 |
| 2013 |
$-172.94 |
| 2012 |
$-257.97 |
| 2011 |
$-314.17 |
| Evoke Pharma Quarterly Basic EPS |
| 2024-09-30 |
$-0.94 |
| 2024-06-30 |
$-0.93 |
| 2024-03-31 |
$-2.04 |
| 2023-12-31 |
$-7.14 |
| 2023-09-30 |
$-6.08 |
| 2023-06-30 |
$-6.71 |
| 2023-03-31 |
$-8.04 |
| 2022-12-31 |
$-6.12 |
| 2022-09-30 |
$-7.20 |
| 2022-06-30 |
$-8.52 |
| 2022-03-31 |
$-9.60 |
| 2021-12-31 |
$-7.68 |
| 2021-09-30 |
$-8.76 |
| 2021-06-30 |
$-10.20 |
| 2021-03-31 |
$-11.53 |
| 2020-12-31 |
$-12.97 |
| 2020-09-30 |
$-11.53 |
| 2020-06-30 |
$-40.35 |
| 2020-03-31 |
$-10.09 |
| 2019-12-31 |
$-7.21 |
| 2019-09-30 |
$-10.09 |
| 2019-06-30 |
$-12.97 |
| 2019-03-31 |
$-15.85 |
| 2018-12-31 |
$-14.41 |
| 2018-09-30 |
$-12.97 |
| 2018-06-30 |
$-20.18 |
| 2018-03-31 |
$-18.74 |
| 2017-12-31 |
$0.00 |
| 2017-09-30 |
$-49.00 |
| 2017-06-30 |
$-15.85 |
| 2017-03-31 |
$-53.32 |
| 2016-12-31 |
$0.00 |
| 2016-09-30 |
$-41.79 |
| 2016-06-30 |
$-59.09 |
| 2016-03-31 |
$-64.85 |
| 2015-12-31 |
$-50.44 |
| 2015-09-30 |
$-60.53 |
| 2015-06-30 |
$-74.94 |
| 2015-03-31 |
$-83.59 |
| 2014-12-31 |
$-70.62 |
| 2014-09-30 |
$-90.79 |
| 2014-06-30 |
$-85.03 |
| 2014-03-31 |
$-70.62 |
| 2013-12-31 |
$-20.18 |
| 2013-09-30 |
$-59.09 |
| 2013-06-30 |
$-30.26 |
| 2013-03-31 |
$-63.41 |
| 2012-12-31 |
|
| 2012-09-30 |
$-61.97 |
| 2012-06-30 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
